Furthermore, the expression of Orai1/STIM1, as well as SOCE activity, is enhanced in cisplatin-resistant ovarian carcinoma cells when compared with the therapy-sensitive parental cells [38]. Here, STIM1 is linked to ovarian carcinoma.